Personalized Theratyping Trial
ConditionCystic Fibrosis
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age6+
SponsorGeorge Solomon
About this trial
The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
Eligibility criteria
Qualifiers
Diagnosis of CF
Age ≥6 y.o.
CFTR mutation that may respond to approved correctors/potentiators in the opinion of the study investigators
Informed Consent/Assent
Disqualifiers
Exacerbation requiring antibiotic or steroids for >28 days before trial entry
Ongoing participation in a CFTR modulator study
Active smoking in the past 6 months
History of solid organ transplant
Trial design
Treatments tested in this trial
- Symdeko
Treatment groups
20 Participants
are divided into 3 treatment groupsSponsors and collaborators
George Solomon
Lead sponsor
University of Alabama at Birmingham
Sponsor institution
Source ClinicalTrials.gov